Innovative Therapies in the nAMD Pipeline: Emerging Biologics and Gene Therapies
Overview
Next-generation biologics and gene therapies for neovascular age-related macular degeneration (nAMD) aim to extend treatment durability and reduce injection frequency. These therapies target multiple pathways beyond VEGF, including inflammation and vascular stabilization, with several agents currently in phase 3 trials showing promising safety and efficacy profiles.
Background
Neovascular age-related macular degeneration (nAMD) is primarily driven by vascular endothelial growth factor (VEGF), and anti-VEGF therapies have been the cornerstone of treatment. However, VEGF is not the sole contributor to disease activity, prompting development of multitargeted agents that inhibit additional growth factors and inflammatory mediators. Advances include engineered antibodies, fusion proteins, multitarget peptides, and gene therapies designed for sustained intraocular protein production. These innovations seek to improve visual outcomes while reducing treatment burden through extended dosing intervals.
Data Highlights
| Therapy | Mechanism | Trial Phase | Key Findings |
|---|---|---|---|
| Tarcocimab Tedromer (KSI-301) | Anti-VEGF antibody biopolymer conjugate | Phase 3 (DAYBREAK) | Noninferior visual acuity gains vs aflibercept; individualized dosing after loading |
| RC28-E | Dual-decoy receptor blocking VEGF-A and FGF-2 | Phase 3 ongoing | Favorable safety; improved BCVA and anatomy in phase 1b |
| AXT107 | Synthetic peptide suppressing VEGF and activating Tie2 | Phase 1/2a | Safety of suprachoroidal injections under evaluation |
| IBI333 | Bispecific fusion protein blocking VEGF-A and VEGF-C | Phase 1 completed | Safety and tolerability assessed; further development unreported |
| Axpaxli (OTX-TKI) | Intravitreal hydrogel implant with axitinib (TKI) | Phase 3 (SOL-1) | Outperformed aflibercept in BCVA and fluid control; supports FDA accelerated approval |
| Duravyu (EYP-1901) | Sustained-delivery intravitreal insert releasing vorolanib (TKI) | Phase 2 | Reduced treatment burden by ≥80% over 12 months with supplemental aflibercept |
Key Findings
- Multitargeted therapies inhibit VEGF plus additional pathways such as FGF, IL-6, Ang-2, and Tie2 to address complex nAMD pathophysiology.
- Tarcocimab tedromer demonstrated noninferior visual acuity gains compared to aflibercept with potential for individualized dosing intervals.
- Axpaxli, a tyrosine kinase inhibitor implant, showed superior efficacy to aflibercept in phase 3 SOL-1 trial, indicating potential for extended dosing every 6 months.
- Gene therapies and sustained-delivery inserts like Duravyu offer promising approaches to reduce injection frequency and treatment burden.
- Some agents, such as sozinibercept (OPT-302), were discontinued after failing to meet primary endpoints in phase 3 trials.
- Several therapies are advancing through late-stage clinical trials, with anticipated data releases and regulatory submissions expected in the coming years.
Clinical Implications
Emerging multitargeted biologics and tyrosine kinase inhibitors may provide clinicians with more durable treatment options for nAMD, potentially reducing injection frequency and improving patient adherence. The integration of these novel agents into clinical practice could enhance visual outcomes by addressing multiple disease pathways simultaneously. Ongoing phase 3 trials will clarify their safety and efficacy profiles to guide future treatment paradigms.
Conclusion
The evolving therapeutic landscape for nAMD includes innovative biologics and gene therapies targeting multiple angiogenic and inflammatory pathways. These next-generation treatments hold promise to improve durability and reduce treatment burden, with several agents nearing regulatory approval.
References
- Regeneron/Genentech -- Current and Emerging Therapies for nAMD
- Kodiak Sciences -- DAYLIGHT and DAYBREAK Trials
- RemeGen Co -- RC28-E Clinical Development
- Ocular Therapeutix -- Axpaxli SOL-1 Trial Data
- EyePoint Pharmaceuticals -- Duravyu Clinical Trials
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.